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Context: Erythrocytosis is one of the most common side effects occurring during testosterone
replacement therapy (TRT) in male hypogonadism. It is well known that all testosterone formu-
lations may cause Hb and hematocrit increase, especially with short-acting injectable formulations.
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a new class of glucose-lowering agents that
reduce hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by inhibition of renal
glucose reabsorption, leading to increased urinary glucose excretion. The co-occurrence of T2DM
and hypogonadism is known to be increasingly frequent. However, to date, no adverse events with
the concomitant use of TRT and SGLT2is are reported.
Case Description: We report two cases of erythrocytosis during testosterone treatment and SGLT2i
in patients with hypogonadism and T2DM.
Conclusion: Considering that hypogonadism and T2DM are frequently associated, clinicians should
carefully monitor the risk of occurrence of erythrocytosis when prescribing TRT and SGLT2i to-
gether. (J Clin Endocrinol Metab 104: 819–822, 2019)
R.C. is a retired 68-year-old nonsmoking man with a10-year history of type 2 diabetes mellitus (T2DM)
treated with metformin 2 g daily, glimepiride 3 mg daily, and
exenatide long-acting release 2 mg once weekly. Referred by
his family physician to the diabetes specialty clinic, R.C.
presentedwith nonoptimal glycemic control and a stable class
I obesitywith no coexisting obstructive sleep apnea syndrome.
He also suffered from noncomplicated arterial hy-
pertension and hypercholesterolemia treated with daily
amlodipine 5 mg, telmisartan 160mg, hydrochlorothiazide
25 mg, and simvastatin 20 mg.
In July 2016, the diabetologist decided to stop glimepiride
and exenatide long-acting release and prescribed a sodium-
glucose cotransporter-2 inhibitor (SGLT2i), dapagliflozin,
10 mg daily.
In his clinical history, he had started testosterone re-
placement therapy (TRT) 7 months before (testosterone
undecanoate injection every 3 months) for primary hypo-
gonadism due to a unilateral orchiectomy at the age of
16 years for cryptorchidism.
Three months after starting SGLT2i, he showed a
7.5-kg weight loss and good glycemic control. His blood
tests showed a severe increase in hematocrit (Hct), Hb,
and red blood cell (RBC) count. His total testosterone
levels were in the normal range (Table 1). White blood
cells and platelet counts were in the normal range.
Upon clinical examination, he appeared well. There
were no signs of hypovolemia or dehydration. Vital signs
were normal. Cardiopulmonary and abdominal evalu-
ation showed no abnormalities.
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As a precautionary measure, the andrologist de-
cided to stop TRT and initiate acetylsalicylic acid,
100 mg daily. The patient was referred to a hema-
tologist who performed a therapeutic phlebotomy to
lower Hct. Molecular testing for JAK2 mutations was
negative.
Seven months after the last testosterone undecanoate
injection and 3 months after phlebotomy, in April
2017, Hb and Hct decreased but remained above the
normal range (Table 1).
During the observation time, there were no reports
of venous thromboembolism, myocardial infarction, or
cerebrovascular accidents.
Case 2
I.M. is a 52-year-old nonsmoking man followed in
our Andrology Unit for a primary hypogonadism after
bilateral orchiectomy for two noncontemporary testic-
ular cancers. He had been on TRT since 2012, first
on transdermal formulation and then on intramuscu-
lar testosterone undecanoate (1000 mg every 10 to
12 weeks) with no adverse events.
He was diagnosed with T2DM in May 2016 with a
medical history of class II obesity complicated by ob-
structive sleep apnea syndrome on continuous positive
airway pressure treatment.
In September 2016, as his glycometabolic control was
not on target, an SGLT2i, empagliflozin 10 mg daily, was
prescribed, in addition to the pre-existing therapy with
metformin 1000 mg/daily.
Four and 7 months after starting the therapy, good
glycemic control and weight loss were achieved, re-
spectively, but, simultaneously, severe increases in Hct,
Hb, and RBCs were observed. White blood cells and
platelet counts were in normal range at all time points.
Total testosterone levels were in the low-normal range
(Table 2). Obstructive sleep apnea syndrome was in good
control with continuous positive airway pressure treatment,
according to the pneumologist’s periodical evaluation.
Upon clinical examination during the diabetologic
follow-up, the patient appeared well with no evidence of
hypovolemia or dehydration. Vital signs were normal.
Cardiopulmonary and abdominal evaluation showed no
abnormalities. There were no reports of venous throm-
boembolism, myocardial infarction, or cerebrovascular


























7 mo After the
Last Testosterone
Injection (April 2017)
HbA1c, % 7.2 7.8 6.9 7.1
Fasting glucose, mg/dL 192 139 158 145
BMI, kg/m2 31.6 31.6 30.1 30.2
Hb, g/dL (NR: 13.5–18.0) 15.7 15.8 18.7–19.4 17.8
Hct, % (NR: 40.0–52.0) 45.9 45.1 55.8–57.1 53.2
RBC count, millions/m3
(NR: 4.50–5.8)
5.1 5.1 6.9–6.1 5.8
Total testosterone, ng/mL
(NR: 2.73–8.16)
2.12 4.72 5.41 2.23
Abbreviation: NR, normal range (according to the local laboratory).
















HbA1c, % 7.3 5.9 5.8 6.3
Fasting glucose, mg/dL 178 129 138 118
BMI, kg/m2 35.6 34.7 34.1 35.0
Hb, g/dL (NR: 13.5–18.0) 16.2 17.2 16.7 16.9
Hct, % (NR: 40.0–52.0) 48.6 56.4 51.9 49.7
RBC count, millions/m3
(NR: 4.50–5.8)




Abbreviation: NR, normal range (according to the local laboratory).
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accidents. The diabetologist decided to continue the
treatment with the SGLT2i, carefully monitoring Hct and
Hb trends, and to temporarily increase the interval be-
tween the following testosterone injections. Follow-up
hormonal data are reported in Table 2.
Discussion
Erythrocytosis is defined as Hct .53% or Hb .18.5
g/dL in men, corresponding to an erythrocyte mass
.125% of that predicted for sex and body mass, al-
though this definition may vary according to Ohlander
et al. (1).
It can be a primary form, arising from a proliferation
of erythrogenic precursors, or be a compensatory re-
sponse to external stimuli leading to erythroid hy-
perplasia (secondary erythrocytosis). Erythrocytosis is
associated with enhanced blood viscosity and platelet
adhesiveness, leading to an increased cardiovascular risk
(1, 2).
Testosterone treatment in hypogonadal men in-
creases, up to 3.15 times, the risk of developing sec-
ondary erythrocytosis (3). This adverse effect is dose
dependent and higher with short-acting rather than
long-acting injectable T-esters and transdermal for-
mulations (1, 4).
Potential mechanisms explaining the relation-
ship between TRT and erythrocytosis include the
direct stimulation of erythroid progenitor cells and
increased production of erythropoietin (EPO) by
the kidneys, but also the suppression of hepcidin,
which subsequently results in augmented iron ab-
sorption and systemic transport, leading to enhanced
erythropoiesis.
To date, no randomized or prospective studies




is recommended to avoid critically el-
evated levels, with 54% considered by
the Endocrine Society as the Hct cutoff
for TRT withdrawal (5).
An increase inHct andHb levels was
also observed in patients with diabetes
treated with SGLT2i, with only few
cases of erythrocytosis (6, 7). This effect
has been related to the diuretic action of
SGLT2i, leading to decreased plasma
volume and hemoconcentration, but
other mechanisms, such as an increased
production of EPO by renal fibroblasts,
are also likely to play a role (8).
In fact, a tubular injury and an excessive glucose
reabsorption occur in diabetes. Moreover, renal fibro-
blasts transform into dysfunctional cells with decreased
EPO secretion, leading to nephrogenic anemia and kid-
ney fibrosis. In this process, which is reversible until renal
tubular injury is mild and not prolonged over time,
SGLT2i reduce the amount of reabsorbed glucose
in the proximal tubules, resulting in restoration of
tubulointerstitial function and increased production of
EPO by fibroblasts (9).
Moreover, the increased renal workload, due to the
excessive glucose reabsorption in diabetes, causes higher
oxygen consumption in the proximal tubules, resulting in
hypoxia, oxidative stress, and a proinflammatory state
that contribute to renal fibroblast dysfunction. Again,
SGLT2i, by decreasing glucose reabsorption, may reverse
these processes.
This is our report of cases of erythrocytosis during
concomitant use of SGLT2i and TRT in patients with
diabetes and hypogonadism. Both conditions, as ex-
plained previously, may have contributed to eryth-
rocytosis, but we postulate that the combination of the
two different drug mechanisms of action may have been
decisive (Fig. 1).
The co-occurrence of T2DM and hypogonadism is
known to be increasingly frequent: about one-third of
men with T2DM and obesity have subnormal free tes-
tosterone concentration and need TRT (10).
Given the frequent association between male hypo-
gonadism and T2DM and the availability of SGLT2i as a
new class of glucose-lowering agents, diabetologists and
andrologists should bear in mind the increased risk of
erythrocytosis during the simultaneous use of testoster-
one and these new antidiabetic drugs.
Both patients provided written informed consent for
the publication of these case reports.
Figure 1. Mechanism proposed for erythrocytosis during concomitant use of SGLT2i and TRT.
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